Conference Posters

This Stream includes all of our Conference Posters Flipbooks

  • PBI-4050 reduces systemic inflammation, electrolyte disturbances and renal injury in mice with sepsis-induced acute kidney injury; role of G

    PBI-4050 reduces systemic inflammation, electrolyte disturbances and renal injury in mice with sepsis-induced acute kidney injury; role of G

    Read PDF
  • Activation of the Free-Fatty Acid Receptor GPR40 Improves Anemia in Mouse Models of Kidney Disease via a Novel EPO-Independent Mechanism of

    Activation of the Free-Fatty Acid Receptor GPR40 Improves Anemia in Mouse Models of Kidney Disease via a Novel EPO-Independent Mechanism of

    Read PDF
  • PBI-4050 decreases adenine-induced tubulointerstitial injury and er-stress; implications of the GPR40 receptor

    PBI-4050 decreases adenine-induced tubulointerstitial injury and er-stress; implications of the GPR40 receptor

    Read PDF
  • PBI-4547 Prevents Progression of Prediabetic Condition to Type 1 Diabetes in NOD Mice

    PBI-4547 Prevents Progression of Prediabetic Condition to Type 1 Diabetes in NOD Mice

    PBI-4547 administration in prediabetic type 1 NOD mice significantly prevented the evolution to severe diabetes resulting in increased survival.

    Read PDF
  • PBI-4547 Improves Glucose Metabolism and Insulin Resistance, and Reduces Liver Damage in a High-Fat Diet Mouse Model of Obesity and Metaboli

    PBI-4547 Improves Glucose Metabolism and Insulin Resistance, and Reduces Liver Damage in a High-Fat Diet Mouse Model of Obesity and Metaboli

    Taken together, these results suggest that PBI-4547 offers the potential as a novel therapy for Non-alcoholic fatty liver disease (NAFLD), obesity, type 2 diabetes mellitus, and associated metabolic s

    Read PDF
  • PBI-4050 Improves Metabolic Regulation and Diabetic Nephropathy through Reduction of ER Stress, Pro-Inflammatory/Fibrotic Markers, Galectin-

    PBI-4050 Improves Metabolic Regulation and Diabetic Nephropathy through Reduction of ER Stress, Pro-Inflammatory/Fibrotic Markers, Galectin-

    These results suggest that PBI-4050 is a strong potential candidate for the treatment of metabolic diseases and related diabetic nephropathy.

    Read PDF
  • PBI-4547 Reverses Diabetes and Metabolic Syndrome through Regulation of Lipid/Glucose Metabolism, Oxidation and Fibrosis in Liver and...

    PBI-4547 Reverses Diabetes and Metabolic Syndrome through Regulation of Lipid/Glucose Metabolism, Oxidation and Fibrosis in Liver and...

    PBI-4547 reduces Blood glucose, cholesterol and triglycerides levels, Pro-inflammatory and pro-fibrotic markers in liver, Adipocyte size and fibrosis in WAT

    Read PDF
  • loading
    Loading More...